Navarrabiomed launches ReproNAGEN, an initiative that will analyze the whole genome of patients with fertility problems

The first meeting of the ReproNAGEN consortium was held last Friday at the headquarters of Navarrabiomed. This new initiative aims to study the impact of human genome analysis in the diagnosis and treatment of couples with fertility problems by creating a personalized diagnostic algorithm and a therapeutic circuit based on the study of the complete parental genome. The project consortium is made up of the University Hospital of Navarre (HUN), the NNBi company and the Navarrabiomed Biomedical Research Center, which directs and coordinates its development. Together, they form a complete team of professionals from very different fields, involved in the use of genomic data for health and development purposes, who will collaborate to make this project a reality.

It should be noted that approximately 1 in 6 people in the world suffer from fertility problems during their reproductive life, or approximately 48 million couples. The usual protocols for the diagnosis of fertility problems and recurrent miscarriages are often ineffective, since idiopathic infertility or recurrent miscarriages of unknown cause persist in a significant proportion of couples.

One of the main limits of in vitro fertilization treatments is the existence of alterations that hinder the interaction of the embryo with the endometrium, necessary for its implantation. The ReproNAGEN project aims to analyze, through genetic sequencing, the genetic cause or set of causes that underlie human infertility problems, in particular those related to poor embryo quality manifesting in the form of embryo failure. recurrent implantation and recurrent miscarriages.

ReproNAGEN has a budget of 1.3 million euros, it is financed by the Directorate General for Industry, Energy and Strategic Projects S4, of the Department of Economic and Business Development, through the call for help to carry out strategic R&D projects that impact initiatives aligned with the sectors identified in Navarre’s Smart Specialization Strategy (S4).

SWIMMING program

Since 2016, Navarrabiomed has been leading the Navarra Strategy in Genomic Medicine of the SNS-O (NAGEN). Since then, and thanks to the support of the Government of Navarre, the center has promoted the development of five strategic projects: NAGENMx, NAGENCOL, NAGENPediatrics, Pharmanagen and NAGEN1000. The common denominator of all these projects is the use of information contained in the human genome to improve the care and treatment of SNS-O patients. The information contained in the genome intersects with other aspects of pathology and information contained in the clinical history. The combination of these sources of information, genomic and clinical, has made it possible to identify the causes of certain diseases, to make more precise diagnoses or to modify the management of patients towards more effective treatments.

These initiatives, associated with Repro-Nagen, make it possible to set up the necessary infrastructures in the SNS-O care circuit so that the information contained in the genome can be used as a method for the diagnosis and treatment of diseases.

Leave a Comment